JP2013515576A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013515576A5 JP2013515576A5 JP2012546244A JP2012546244A JP2013515576A5 JP 2013515576 A5 JP2013515576 A5 JP 2013515576A5 JP 2012546244 A JP2012546244 A JP 2012546244A JP 2012546244 A JP2012546244 A JP 2012546244A JP 2013515576 A5 JP2013515576 A5 JP 2013515576A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- therapeutic agent
- tissue penetrating
- capsule
- penetrating member
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 claims description 96
- 229940124597 therapeutic agent Drugs 0.000 claims description 76
- 230000000149 penetrating effect Effects 0.000 claims description 68
- 239000002775 capsule Substances 0.000 claims description 40
- 238000002360 preparation method Methods 0.000 claims description 37
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 25
- 239000000463 material Substances 0.000 claims description 13
- -1 arubyglutide Chemical compound 0.000 claims description 10
- 239000000859 incretin Substances 0.000 claims description 10
- 230000033001 locomotion Effects 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 9
- 239000008103 glucose Substances 0.000 claims description 9
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 claims description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 7
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims description 6
- 108010011459 Exenatide Proteins 0.000 claims description 6
- 229960001519 exenatide Drugs 0.000 claims description 6
- 102000004877 Insulin Human genes 0.000 claims description 5
- 108090001061 Insulin Proteins 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 229940125396 insulin Drugs 0.000 claims description 5
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 claims description 4
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 claims description 4
- 230000015556 catabolic process Effects 0.000 claims description 4
- 238000002144 chemical decomposition reaction Methods 0.000 claims description 4
- 238000006731 degradation reaction Methods 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 230000000717 retained effect Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 230000009747 swallowing Effects 0.000 claims description 4
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 2
- 108010019598 Liraglutide Proteins 0.000 claims description 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims description 2
- 229960002701 liraglutide Drugs 0.000 claims description 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims description 2
- 108010048573 taspoglutide Proteins 0.000 claims description 2
- WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 claims description 2
- 229950007151 taspoglutide Drugs 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 43
- 210000000813 small intestine Anatomy 0.000 description 26
- 229940079593 drug Drugs 0.000 description 20
- 230000000968 intestinal effect Effects 0.000 description 16
- 239000007788 liquid Substances 0.000 description 13
- 230000002411 adverse Effects 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 210000000936 intestine Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000000376 reactant Substances 0.000 description 8
- 229940123208 Biguanide Drugs 0.000 description 5
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 5
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 108010051696 Growth Hormone Proteins 0.000 description 4
- 102000018997 Growth Hormone Human genes 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000003982 Parathyroid hormone Human genes 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- 230000000573 anti-seizure effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229960001319 parathyroid hormone Drugs 0.000 description 3
- 239000000199 parathyroid hormone Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 229960003883 furosemide Drugs 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- PJRSUKFWFKUDTH-JWDJOUOUSA-N (2s)-6-amino-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]propanoyl]amino]acetyl]amino]propanoyl Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(N)=O PJRSUKFWFKUDTH-JWDJOUOUSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 229920005570 flexible polymer Polymers 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108010021753 peptide-Gly-Leu-amide Proteins 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28476609P | 2009-12-24 | 2009-12-24 | |
| US61/284,766 | 2009-12-24 | ||
| US34033110P | 2010-03-15 | 2010-03-15 | |
| US61/340,331 | 2010-03-15 | ||
| US39530410P | 2010-05-10 | 2010-05-10 | |
| US61/395,304 | 2010-05-10 | ||
| PCT/US2010/062070 WO2011079302A2 (en) | 2009-12-24 | 2010-12-23 | Swallowable drug delivery device and methods of drug delivery |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015115816A Division JP2015186590A (ja) | 2009-12-24 | 2015-06-08 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013515576A JP2013515576A (ja) | 2013-05-09 |
| JP2013515576A5 true JP2013515576A5 (enExample) | 2014-02-20 |
Family
ID=44196421
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012546244A Withdrawn JP2013515576A (ja) | 2009-12-24 | 2010-12-23 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
| JP2015115816A Withdrawn JP2015186590A (ja) | 2009-12-24 | 2015-06-08 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
| JP2016196141A Active JP6484208B2 (ja) | 2009-12-24 | 2016-10-04 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
| JP2018046568A Withdrawn JP2018110907A (ja) | 2009-12-24 | 2018-03-14 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
| JP2020002601A Active JP7590811B2 (ja) | 2009-12-24 | 2020-01-10 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
| JP2021072584A Active JP7616937B2 (ja) | 2009-12-24 | 2021-04-22 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
| JP2023092726A Withdrawn JP2023116591A (ja) | 2009-12-24 | 2023-06-05 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015115816A Withdrawn JP2015186590A (ja) | 2009-12-24 | 2015-06-08 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
| JP2016196141A Active JP6484208B2 (ja) | 2009-12-24 | 2016-10-04 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
| JP2018046568A Withdrawn JP2018110907A (ja) | 2009-12-24 | 2018-03-14 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
| JP2020002601A Active JP7590811B2 (ja) | 2009-12-24 | 2020-01-10 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
| JP2021072584A Active JP7616937B2 (ja) | 2009-12-24 | 2021-04-22 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
| JP2023092726A Withdrawn JP2023116591A (ja) | 2009-12-24 | 2023-06-05 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
Country Status (11)
| Country | Link |
|---|---|
| EP (4) | EP4056173B1 (enExample) |
| JP (7) | JP2013515576A (enExample) |
| CN (2) | CN102905753B (enExample) |
| AU (5) | AU2010336330B2 (enExample) |
| CA (1) | CA2785168C (enExample) |
| DK (3) | DK3756657T3 (enExample) |
| ES (2) | ES2804716T3 (enExample) |
| FI (1) | FI3756657T3 (enExample) |
| PL (2) | PL3756657T3 (enExample) |
| PT (1) | PT3756657T (enExample) |
| WO (1) | WO2011079302A2 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102770151B (zh) | 2009-08-03 | 2018-07-31 | 因卡伯实验室有限责任公司 | 用于刺激肠道内肠促胰岛素产生的吞咽式囊和方法 |
| US8562589B2 (en) | 2009-12-24 | 2013-10-22 | Rani Therapeutics, Llc | Swallowable drug delivery device and method of delivery |
| AU2010336330B2 (en) | 2009-12-24 | 2016-04-28 | Rani Therapeutics, Llc | Swallowable drug delivery device and methods of drug delivery |
| CN103025319B (zh) * | 2010-03-10 | 2015-07-01 | 因卡伯实验室有限责任公司 | 用于利用可吞咽式药剂递送装置递送到肠道内腔中的治疗剂制剂 |
| US9259386B2 (en) | 2010-12-23 | 2016-02-16 | Rani Therapeutics, Llc | Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402806B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8809269B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9629799B2 (en) | 2010-12-23 | 2017-04-25 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9283179B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8809271B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402807B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8734429B2 (en) | 2010-12-23 | 2014-05-27 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
| US8980822B2 (en) | 2010-12-23 | 2015-03-17 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8846040B2 (en) | 2010-12-23 | 2014-09-30 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US10639272B2 (en) | 2010-12-23 | 2020-05-05 | Rani Therapeutics, Llc | Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8764733B2 (en) | 2010-12-23 | 2014-07-01 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9284367B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9415004B2 (en) | 2010-12-23 | 2016-08-16 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9149617B2 (en) | 2010-12-23 | 2015-10-06 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
| US9861683B2 (en) | 2010-12-23 | 2018-01-09 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8969293B2 (en) | 2010-12-23 | 2015-03-03 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| NO3117865T3 (enExample) | 2011-01-21 | 2018-04-07 | ||
| PL3653223T3 (pl) | 2011-06-29 | 2021-12-20 | Rani Therapeutics, Llc | Urządzenie do doustnego dostarczania związków leczniczych |
| PL2726091T3 (pl) * | 2011-06-29 | 2020-08-10 | Rani Therapeutics, Llc | Preparaty lecznicze dostarczane do kanału przewodu jelitowego za pomocą połykalnego urządzenia dostarczającego lek |
| CA2901923C (en) * | 2013-03-15 | 2021-12-07 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
| US20150064241A1 (en) * | 2013-09-05 | 2015-03-05 | Google Inc. | Delivery of Functionalized Particles |
| CN103479401B (zh) * | 2013-09-29 | 2015-08-19 | 中山大学附属第一医院 | 一种肠道生物标志物采样器 |
| US10689460B2 (en) | 2014-05-15 | 2020-06-23 | Incube Labs, Llc | PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| EP3142645A4 (en) | 2014-05-15 | 2017-12-27 | Rani Therapeutics, LLC | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
| JP6666858B2 (ja) * | 2014-06-11 | 2020-03-18 | マサチューセッツ インスティテュート オブ テクノロジー | 滞留構造体および関連方法 |
| WO2016155671A1 (zh) * | 2015-04-02 | 2016-10-06 | 傅君志 | 可吞咽式装置 |
| CA2984422C (en) * | 2015-05-08 | 2023-10-17 | Incube Labs, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| EP3347050B1 (en) * | 2015-09-08 | 2025-01-15 | Rani Therapeutics, LLC | Pcsk9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| EP3426263A4 (en) * | 2016-03-09 | 2019-10-16 | Incube Labs, LLC | METHOD AND ARTICLE FOR THE DELIVERY OF LIVABLE CELLS IN SOLID TISSUE |
| US20180070857A1 (en) | 2016-09-09 | 2018-03-15 | Progenity Inc. | Electromechanical ingestible device for delivery of a dispensable substance |
| FR3059553B1 (fr) * | 2016-12-07 | 2021-04-23 | Univ Grenoble Alpes | Dispositif implantable |
| CA3046023A1 (en) * | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunosuppressant |
| CN107050578A (zh) * | 2017-05-04 | 2017-08-18 | 梁曦 | 一种药物自动注射装置 |
| IL301683B2 (en) * | 2017-05-17 | 2025-02-01 | Massachusetts Inst Technology | Self-healing systems and related components and methods |
| IL270674B2 (en) * | 2017-05-19 | 2024-12-01 | Shalon Tidhar | Instruments and methods for collecting samples from the digestive system |
| CN115844361A (zh) * | 2017-06-12 | 2023-03-28 | 拉尼医疗有限公司 | 用于测定胃排空参数的可吞咽胶囊、系统和方法 |
| CN108324231A (zh) * | 2018-03-14 | 2018-07-27 | 潍坊学院 | 一种自清洁上药胶囊内镜 |
| SG11202009767PA (en) | 2018-04-10 | 2020-10-29 | Panacea Biomatx Inc | Method and system for making personalized nutritional and pharmaceutical formulations using additive manufacturing |
| US10675248B2 (en) * | 2018-08-14 | 2020-06-09 | Alma Therapeutics Ltd. | Expandable pill |
| WO2020036972A1 (en) * | 2018-08-15 | 2020-02-20 | Lyndra, Inc. | Systems for enteric delivery of therapeutic agents |
| US12128201B2 (en) | 2018-08-23 | 2024-10-29 | Baywind Bioventures | Capsule device for delivery of active agent to gastrointestinal tract |
| US12128133B2 (en) * | 2018-09-25 | 2024-10-29 | Rani Therapeutics, Llc | Ingestible device with expandable enclosure |
| CN116726362A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| EP3917596A1 (en) * | 2019-02-01 | 2021-12-08 | Novo Nordisk A/S | Medical device with actuation mechanism |
| US11771829B2 (en) | 2019-02-01 | 2023-10-03 | Massachusetts Institute Of Technology | Systems and methods for liquid injection |
| US11833319B2 (en) * | 2019-03-01 | 2023-12-05 | Rani Therapeutics, Llc | Propulsive drug delivery from a swallowable device into a patients intestinal tract |
| WO2020245448A1 (en) * | 2019-06-07 | 2020-12-10 | Novo Nordisk A/S | Ingestible device with delivery member detachment |
| US11793980B2 (en) * | 2019-08-31 | 2023-10-24 | Celero Systems, Inc. | Intestinal attachment device |
| MX2022004189A (es) * | 2019-10-08 | 2022-09-26 | Incube Labs Llc | Dispositivo de suministro de formulación de liberación controlada. |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| WO2021146296A1 (en) * | 2020-01-14 | 2021-07-22 | Rani Therapeutics, Llc | Swallowable devices for drug delivery in an intestinal tract |
| CA3170332A1 (en) * | 2020-02-18 | 2021-08-26 | Rani Therapeutics, Llc | Injection of a therapeutic formulation into a wall of the gastrointestinal tract |
| WO2021198353A1 (en) * | 2020-03-31 | 2021-10-07 | Danmarks Tekniske Universitet | A flexible foil for the delivery of therapeutic cargos |
| US20230240665A1 (en) * | 2020-06-29 | 2023-08-03 | The Governing Council Of The University Of Toronto | Magnetically actuated capsule |
| CN111772589B (zh) * | 2020-08-04 | 2022-07-12 | 重庆金山医疗技术研究院有限公司 | 一种判断胶囊内镜是否适用的检测系统及其探路胶囊 |
| JP7654068B2 (ja) * | 2020-09-16 | 2025-03-31 | イーライ リリー アンド カンパニー | 拡張アームを有する経口薬物送達デバイス |
| WO2023002270A1 (en) * | 2021-07-19 | 2023-01-26 | Cochlear Limited | Self-propelled pharmaceutical delivery capsules |
| CN113598690B (zh) * | 2021-08-10 | 2023-07-28 | 安徽光阵光电科技有限公司 | 一种用于人体体内医疗的内窥镜药丸 |
| EP4482559A1 (en) * | 2022-02-21 | 2025-01-01 | Rani Therapeutics, LLC | Devices, assemblies, and methods for delivering a fluid preparation into a gastrointestinal tract |
| CN119424884B (zh) * | 2024-09-29 | 2025-10-10 | 北京水木金昇医疗科技服务有限公司 | 一种递送注射药物的微针胶囊及其应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474785A (en) * | 1990-01-24 | 1995-12-12 | Alza Corporation | Delivery system comprising means for controlling internal pressure |
| US5217449A (en) * | 1990-12-11 | 1993-06-08 | Miyarisan Kabushiki Kaisha | Medical capsule and apparatus for activating the same |
| DK42093D0 (da) | 1993-04-07 | 1993-04-07 | Bukh Meditec | Administrationsmetode |
| US6743211B1 (en) * | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
| EP1200140A1 (en) | 1999-08-03 | 2002-05-02 | Smith & Nephew, Inc. | Controlled release implantable devices |
| US6478776B1 (en) | 2000-04-05 | 2002-11-12 | Biocardia, Inc. | Implant delivery catheter system and methods for its use |
| GB0017999D0 (en) * | 2000-07-21 | 2000-09-13 | Smithkline Beecham Biolog | Novel device |
| JP4643089B2 (ja) * | 2001-09-27 | 2011-03-02 | オリンパス株式会社 | カプセル型医療装置 |
| JP2002186672A (ja) * | 2001-09-28 | 2002-07-02 | Olympus Optical Co Ltd | 医療用カプセル装置 |
| FR2835730B1 (fr) * | 2002-02-11 | 2004-12-10 | C T M Ct De Transfert Des Micr | Dispositif pour la delivrance de substances et le prelevement intracorporel |
| WO2004000389A2 (en) | 2002-06-25 | 2003-12-31 | Sung-Yun Kwon | Rapidly dissolving micro-perforator for drug delivery and other applications |
| US7118531B2 (en) * | 2002-09-24 | 2006-10-10 | The Johns Hopkins University | Ingestible medical payload carrying capsule with wireless communication |
| AU2003288516A1 (en) * | 2002-12-26 | 2004-07-22 | Given Imaging Ltd. | Immobilizable in vivo sensing device |
| RU2334506C2 (ru) * | 2003-01-29 | 2008-09-27 | И-Пилл Фарма Лтд. | Активная доставка лекарственного средства в желудочно-кишечном тракте |
| US20050058701A1 (en) * | 2003-01-29 | 2005-03-17 | Yossi Gross | Active drug delivery in the gastrointestinal tract |
| JP2005021677A (ja) * | 2003-06-10 | 2005-01-27 | Medorekkusu:Kk | 経皮投薬用パッドベース、及び注射針 |
| US8000784B2 (en) * | 2004-04-19 | 2011-08-16 | The Invention Science Fund I, Llc | Lumen-traveling device |
| DE102004026615A1 (de) † | 2004-06-01 | 2005-12-29 | Siemens Ag | Vorrichtung und Verfahren zur Freisetzung eines in das Körperinnere eines Patienten geführten therapeutischen Mittels |
| US20060153894A1 (en) * | 2004-06-30 | 2006-07-13 | Ragae Ghabrial | Multi-compartment delivery system |
| DE112005002806A5 (de) * | 2004-09-13 | 2007-08-30 | Luk Lamellen Und Kupplungsbau Beteiligungs Kg | Verfahren zur Lagebestimmung bei einem EC-Motor |
| US20070265598A1 (en) * | 2004-09-30 | 2007-11-15 | Duocure, Inc. | Device and Method for Treating Weight Disorders |
| EP1841490A2 (en) * | 2005-01-18 | 2007-10-10 | Koninklijke Philips Electronics N.V. | Electronically controlled capsule |
| CN101184523B (zh) * | 2005-05-27 | 2011-04-13 | 奥林巴斯株式会社 | 被检体内导入装置 |
| US20070078414A1 (en) | 2005-08-05 | 2007-04-05 | Mcallister Devin V | Methods and devices for delivering agents across biological barriers |
| JP4402648B2 (ja) * | 2005-12-16 | 2010-01-20 | オリンパス株式会社 | 被検体内導入装置 |
| CA2635337C (en) | 2005-12-30 | 2015-02-17 | Nir Barak | Device for treating the anal sphincter |
| GB0603252D0 (en) * | 2006-02-17 | 2006-03-29 | Axcess Ltd | Dissolution aids for oral peptide delivery |
| US7741273B2 (en) | 2006-04-13 | 2010-06-22 | Warsaw Orthopedic, Inc. | Drug depot implant designs |
| DE102006047537B4 (de) * | 2006-10-07 | 2024-05-16 | Sanofi-Aventis Deutschland Gmbh | Verfahren und Vorrichtung zur Bestimmung der Position eines Stopfens einer Ampulle für ein Arzneimittel in einem medizinischen Gerät sowie deren Verwendung, ein entsprechendes medizinisches Gerät sowie Herstellung eines medizinischen Geräts |
| US20080214919A1 (en) * | 2006-12-26 | 2008-09-04 | Lifescan, Inc. | System and method for implementation of glycemic control protocols |
| EP2196131A4 (en) * | 2007-09-26 | 2012-12-05 | Olympus Medical Systems Corp | INTRODUCTION SYSTEM IN A SUBJECT |
| AU2010336330B2 (en) | 2009-12-24 | 2016-04-28 | Rani Therapeutics, Llc | Swallowable drug delivery device and methods of drug delivery |
-
2010
- 2010-12-23 AU AU2010336330A patent/AU2010336330B2/en active Active
- 2010-12-23 DK DK20164025.7T patent/DK3756657T3/da active
- 2010-12-23 FI FIEP20164025.7T patent/FI3756657T3/fi active
- 2010-12-23 JP JP2012546244A patent/JP2013515576A/ja not_active Withdrawn
- 2010-12-23 DK DK18191328.6T patent/DK3461478T3/da active
- 2010-12-23 DK DK22166190.3T patent/DK4056173T3/da active
- 2010-12-23 CN CN201080064664.4A patent/CN102905753B/zh active Active
- 2010-12-23 PL PL20164025.7T patent/PL3756657T3/pl unknown
- 2010-12-23 EP EP22166190.3A patent/EP4056173B1/en active Active
- 2010-12-23 CA CA2785168A patent/CA2785168C/en active Active
- 2010-12-23 ES ES18191328T patent/ES2804716T3/es active Active
- 2010-12-23 PT PT201640257T patent/PT3756657T/pt unknown
- 2010-12-23 ES ES20164025T patent/ES3031275T3/es active Active
- 2010-12-23 EP EP18191328.6A patent/EP3461478B1/en not_active Revoked
- 2010-12-23 WO PCT/US2010/062070 patent/WO2011079302A2/en not_active Ceased
- 2010-12-23 EP EP20164025.7A patent/EP3756657B1/en active Active
- 2010-12-23 PL PL18191328T patent/PL3461478T3/pl unknown
- 2010-12-23 EP EP10840193.6A patent/EP2515992B2/en active Active
- 2010-12-23 CN CN201610322529.4A patent/CN105999526B/zh active Active
-
2015
- 2015-06-08 JP JP2015115816A patent/JP2015186590A/ja not_active Withdrawn
-
2016
- 2016-07-28 AU AU2016208382A patent/AU2016208382B2/en active Active
- 2016-10-04 JP JP2016196141A patent/JP6484208B2/ja active Active
-
2018
- 2018-03-14 JP JP2018046568A patent/JP2018110907A/ja not_active Withdrawn
- 2018-05-15 AU AU2018203418A patent/AU2018203418B2/en active Active
-
2020
- 2020-01-10 JP JP2020002601A patent/JP7590811B2/ja active Active
- 2020-05-08 AU AU2020203067A patent/AU2020203067B2/en active Active
-
2021
- 2021-04-22 JP JP2021072584A patent/JP7616937B2/ja active Active
-
2022
- 2022-11-04 AU AU2022263569A patent/AU2022263569B2/en not_active Expired - Fee Related
-
2023
- 2023-06-05 JP JP2023092726A patent/JP2023116591A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013515576A5 (enExample) | ||
| US12268831B2 (en) | Swallowable drug delivery device and methods of drug delivery | |
| US11684761B2 (en) | Preparation comprising exanatide for delivery into a lumen of the intestinal tract | |
| US11844867B2 (en) | Method of delivering insulin into a lumen of the intestinal tract using a swallowable drug delivery device | |
| US11813314B2 (en) | Method of delivering a somatostatin compound into a lumen of the intestinal tract using a swallowable drug delivery device | |
| US10967050B2 (en) | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device | |
| EP3756657B1 (en) | Swallowable drug delivery device | |
| US20180008771A1 (en) | Device, system and methods for the oral delivery of therapeutic compounds | |
| HK40044998B (en) | Swallowable drug delivery device | |
| HK40044998A (en) | Swallowable drug delivery device | |
| HK40077106A (en) | Swallowable drug delivery device |